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Abstract
Background: Several short antimicrobial peptides that are rich in tryptophan and arginine residues were designed with a
series of simple modifications such as end capping and cyclization. The two sets of hexapeptides are based on the Trp- and
Arg-rich primary sequences from the ‘‘antimicrobial centre’’ of bovine lactoferricin as well as an antimicrobial sequence
obtained through the screening of a hexapeptide combinatorial library.
Methodology/Principal Findings: HPLC, mass spectrometry and antimicrobial assays were carried out to explore the
consequences of the modifications on the serum stability and microbicidal activity of the peptides. The results show that C-
terminal amidation increases the antimicrobial activity but that it makes little difference to its proteolytic degradation in
human serum. On the other hand, N-terminal acetylation decreases the peptide activities but significantly increases their
protease resistance. Peptide cyclization of the hexameric peptides was found to be highly effective for both serum stability
and antimicrobial activity. However the two cyclization strategies employed have different effects, with disulfide cyclization
resulting in more active peptides while backbone cyclization results in more proteolytically stable peptides. However, the
benefit of backbone cyclization did not extend to longer 11-mer peptides derived from the same region of lactoferricin.
Mass spectrometry data support the serum stability assay results and allowed us to determine preferred proteolysis sites in
the peptides. Furthermore, isothermal titration calorimetry experiments showed that the peptides all had weak interactions
with albumin, the most abundant protein in human serum.
Conclusions/Significance: Taken together, the results provide insight into the behavior of the peptides in human serum
and will therefore aid in advancing antimicrobial peptide design towards systemic applications.
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Introduction
Cationic antimicrobial peptidesareanessential component ofthe
defense systems of organisms throughout nature and they offer
protection from invading pathogens [1]. Over the last two decades,
research has blossomed in this field with the ultimate aim of
developing antimicrobial peptides into viable alternatives for
antibiotics that can act on multidrug-resistant bacteria, which are
becoming increasingly prevalent [2]. The advantage of antimicro-
bial peptides is the generality of their mechanism of action, which
involves either compromising the bacterial membrane integrity or
disrupting essential components inside the cells [3,4]. This differs
from the specific receptors targeted by conventional antibiotics
which allow the pathogenic bacteria to develop resistance more
rapidly. Furthermore, antimicrobial peptides are fast-acting and
biodegradable, which alleviates the current concern over residual
antibiotics in the environment. In addition to their direct
microbicidal activities, these host defense peptides are particularly
attractive because of the multiple activities that are associated with
many members of this family. These include the regulation of the
innate and adaptive immune systems, inflammation and wound
healing [1,2], and additional anti-infective activities such as being
antifungal, antiviral, antiparasitic or anticancerous [5–8].
The development of antimicrobial peptides for clinical use has
thus far been limited to topical applications [2]. Although they
could in principle be used systemically, proteolytic degradation
and efficient peptide clearance pose as significant obstacles in the
dynamic circulatory system. This problem is compounded by the
relatively high cost of production of synthetic peptides, thereby
making shorter peptide candidates more desirable [9,10]. Many
design strategies have been employed to date to optimize
antimicrobial activity and selectivity. Through such peptide
engineering, the peptides can also be made less susceptible to
serum proteases. For example, modifications with unnatural
amino acids such as D-amino acids [9], derivatives with unnatural
side chains [11], and b-amino acids [12] have been shown to
improve the stability and activity in several cases. Cationic
compounds with stable steroid backbones resembling antimicro-
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a viable strategy to constrain the peptide structure and thereby
enhance antimicrobial activity. For example, this can be achieved
by joining the terminal ends of a peptide by a disulfide bridge
[14–17]. Thisapproach hasbeen used for an analogue of indolicidin,
an antimicrobial peptide isolated from bovine neutrophils, where a
disulfide-bridged peptide was more resistant to trypsin degradation
than its linear counterpart [15]. Head-to-tail backbone cyclization
is another effective modification to constrain the peptide structure
[18–20], and it has the added advantage of eliminating any suscepti-
bility to exoproteases [21]. In fact, natureproduces a number of cyclic
antimicrobial peptides itself such as rhesus theta-defensin [22],
microcin J25 [23] and daptomycin [24].
Antimicrobial peptide administration into the circulatory system
raisesa numberof concerns regardingtheir activity, as they maynot
be as effective as observed in in vitro assays. Many peptides can be
inactivated by physiological salt concentrations, as exemplified by
the b-defensins [25,26], magainin [27] and LL-37 [28]. However,
several peptides have salt-insensitive activities including clavinin
[27], protegrin [29] and tachyplesin [30]. In fact, some synthetic a-
helical peptides have been engineered to be salt-resistant by fine-
tuning the amphipathicity and stability of the a-helix [31,32].
Possible interactions with serum proteins may also impede activity,
particularly when the peptides bind to abundant proteins in blood
plasma such as human serum albumin (HSA). Recently, a set of
cationicantimicrobial tripeptideswerefound to interact withbovine
serum albumin (BSA) with micromolar affinities, and their
antimicrobial activities were reduced five-fold or more in BSA-
supplementedassays[33]. This effectwasalsoobserved with human
b-defensin-3 where the addition of HSA reduced its activity against
Acinetobacter baumannii and abolished its activity against Staphylococcus
aureus [25]. Despite these obstacles, the successful use of some
antimicrobial peptides for treating specific infections has been
demonstrated inmousemodels[34–37].Moreover,injected peptide
drugs are now becoming more commonly used, for example in the
treatment of HIV and chronic pain [38,39].
In this study, the serum stabilities of two sets of hexameric
antimicrobial peptide sequences were tested. The first group
of peptides is based on the primary sequence RRWQWR. This
sequence has been referred to as the antimicrobial center of bovine
lactoferricin(LfcinB)[40].LfcinBitselfis an antimicrobial 25-residue
peptidethat isreleased fromthecationicN-terminalregionofbovine
lactoferrinuponpepsindigestioninthegastrointestinaltract[8].The
sequence ofthe second groupof peptides, RRWWRF, was identified
through screening of a synthetic combinatorial hexapeptide library
and is hereafter named Combi in this study [41]. These two
sequences highlight the importance of tryptophan and arginine
residues in short antimicrobial peptides. The Arg side chains provide
positive charges as well as hydrogen bonding capabilities to attract
the peptides to the negatively charged phospholipid headgroups of
the bacterial membranes, and the indole side chains of Trp have a
preference for the interfacial region of lipid bilayers [3,42,43]. While
membrane interactions are important for these peptides [44],
confocal microscopy data obtained for the Combi peptide and
several analogs show that they can rapidly become localized in
the cytoplasm of bacterial cells, which suggests that they act on
intracellular targets and that they are not strongly membrane-active
[9,45].
The variations within the group of peptides studied here involve
well established simple peptide modifications. These include
acetylation and/or amidation of the N- and C-termini, respectively,
which allows us to examine how neutralization of the terminal
charges influences their susceptibility towards exopeptidases.
Carboxyamidation has been a popular modification in synthetic
and naturally occurring antimicrobial peptides because of the
removal of the carboxyterminal negative charge, which normally
gives rise to an increased activity [46,47]. In some cases, this specific
modification may also lead to the stabilization of the peptide
structure [48]. The LfcinB-derived hexamer was originally studied
with a free N-terminus and an amidated C-terminus, and the
Combi peptide was originally studied with both of these
modifications.Thehexapeptideswerealsocyclized bybothdisulfide
crosslinking and head-to-tail linking of the peptide backbone for
comparison [21]. The backbone-cyclized version of the Combi
peptide has earlier been shown to possess increased antimicrobial
potency [18], however its stability against degradation has not yet
been studied. To complement our studies with the hexameric
peptides, we also studied linear and cyclic derivatives incorporating
eleven residues from LfcinB [14] to explore the effect of peptide
length on peptide stability in serum. The amino acid sequences of
the peptide variants studied here are listed in Table 1. To determine
their stability in human serum, peptide amounts were quantified by
HPLC and mass spectrometry was used to identify the fragments
produced. The antimicrobial activity of all the modified peptides
was also determined so that peptides with both optimal stability and
activity could be identified. Finally, the interactions between these
peptides and human and bovine serum albumin were investigated
by isothermal titration calorimetry (ITC) to further characterize
their behavior in the bloodstream.
Results
Stabilities in human serum
To investigate the effects of the modifications on proteolytic
susceptibility, the disappearance of the intact peptides incubated in
diluted human serum at 37uC was followed by RP-HPLC. A
sample set of chromatograms is shown for Lfc9 in Fig. 1.
Table 1. Sequences and net charges of the short LfcinB and
Combi peptides.
Peptide Sequence
a Net charge at pH 7.0
Lfc1 RRWQWR +3
Lfc2 RRWQWR-NH2 +4
Lfc3 CH3CO-RRWQWR +2
Lfc4 CH3CO-RRWQWR-NH2 +3
Lfc5 -RRWQWR- +3
Lfc6 CRRWQWRC-NH2 +4
Lfc7 RRWQWRMKKLG +5
Lfc8 -RRWQWRMKKLG- +5
Lfc9 CRRWQWRMKKLGC-NH2 +6
Com1 RRWWRF +3
Com2 RRWWRF-NH2 +4
Com3 CH3CO-RRWWRF +2
Com4 CH3CO-RRWWRF-NH2 +3
Com5 -RRWWRF- +3
Com6 CRRWWRFC-NH2 +4
Com7 CH3CO-CRRWWRFC-NH2 +3
aHyphens around certain sequences represent head-to-tail backbone
cyclization; underlined sequences denote peptides with disulfide bridging
between the terminal Cys residues.
doi:10.1371/journal.pone.0012684.t001
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longer. Overall results in Fig. 2 display only the course of
degradation up to 6.5 h to highlight the differences in the profiles
of the rapidly degraded peptides.
The linear hexamers show little difference between LfcinB- and
Combi-based primary sequences (Fig. 2A and B). The peptides with
free N- and C-termini, Lfc1 and Com1, are degraded quickly with
half-lives of less than 0.5 h and are completely gone after 2 h. Lfc2
and Com2 show very similar profiles for the non-modified peptides,
suggesting that C-terminal amidation does not protect against
carboxypeptidase activity in human serum. The N-acetylated
hexamers seem to confer some stability against aminopeptidases,
as both Lfc3 and Com3 have half-lives of about 1 h. However both
peptides are still almost fully degraded after 2 h. Protecting both
ends of the peptides gives them a greater stability beyond the
additive contributions of the individual modifications. The capped
hexamers have half-lives of ,1.5 h with Lfc4 being notably more
resistant than Com4.
In contrast, cyclization of the short peptides generally brings
about significant stabilization against serum proteases (Fig. 2C and
D). Lfc5 and Com5 are both remarkably resilient and more than
70% of these peptides remain intact after 6.5 h. 24 h serum
incubations were also carried out for these peptides and their levels
at this time period were ,50%. The disulfide bonded short
peptides are more susceptible to degradation. In fact, Lfc6 has a
degradation profile similar to that of Lfc4. Com6 and Com7 are
more resistant with ,50% intact peptide left after an incubation
Figure 1. An example set of HPLC chromatograms from various
time points of Lfc9 incubated in 25% human male serum at
37uC, showing the degradation of the intact peptide (,13 mL
ret. vol.) and appearance of its partially digested products (5–
11 mL ret. vol.).
doi:10.1371/journal.pone.0012684.g001
Figure 2. Serum stability profiles of the LfcinB- and Combi-based peptides. Relative peptide concentrations were determined by
integration of the A215 peaks from RP-HPLC chromatograms. A) Linear LfcinB hexamers showing individual and combined effects of C-
terminal amidation and N-terminal acetylation, B) Linear Combi hexamers with end caps C) Linear and cyclized LfcinB peptides comparing the end-to-
end disulfide bridging and head-to-tail backbone cyclization strategies to different sized peptides, and D) cyclized Combi peptides. Assays were
performed in triplicate.
doi:10.1371/journal.pone.0012684.g002
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the gradual degradation. Com6 is initially degraded more slowly
than Com7, which is unexpected given the results of their linear
counterparts. Nevertheless, their levels stabilized after 6.5 h.
The linear 11-mer LfcinB peptide, Lfc7, is slightly less degraded
in serum compared to the hexameric Lfc1. The cyclized analogues
are considerably more resistant to the serum proteases than Lfc7,
however their levels all approach 0% intact peptide remaining
after 6.5 h. The stability observed for the hexameric Lfc5 does not
translate to the longer 11-residue cyclic peptide, Lfc8. Instead, the
latter peptide’s degradation profile is similar to that of Lfc9.
Mass spectrometry characterization of intermediate
fragments
To examine the cleavage patterns of the peptides in serum,
aliquots of each incubation mixture were taken at the 75 min time
point to be analyzed by MALDI mass spectrometry. The peptides
which had observable intermediate fragments are reported in
Table 2 with cleavage product identification. For the hexamers
with free termini or an amidated C-terminus, no intermediates
were recovered. This is probably due to the fast degradation of
these peptides in the diluted serum. The acetylated hexamers do
have identifiable fragments which correspond to the loss of the last
two or three residues. The same fragments are recovered in the
peptides that also have amidated C-termini, which indicates that
the loss of the last two or three residues is not due to
carboxypeptidase activity. Instead, there are clear recognition
sites for endoproteases. No intermediates were recovered from
incubations with the cyclic hexamers except for a nicked Lfc5.
This may be due to the additional backbone rigidity of these
peptides that would decrease possible interactions with proteases.
The intermediate fragments recovered from Lfc8 help to explain
its lowered stability. A notable cleavage site is present preceding
either the last or the penultimate residue of the sequence when
the peptide backbone extends well beyond those residues as in
Lfc8, whereas with Lfc7, there may not be enough of a peptide
extension to have proper interactions with the same endopepti-
dase.
Interactions with serum albumins by ITC
The potential for interactions between various peptides and
bovine and human serum albumin (BSA and HSA) were studied
by microcalorimetry. The results were similar for all peptides
regardless of primary sequence, cyclization, length and source of
albumin. Examples of two ITC profiles can be found in Fig. S1.
Two-site modeling was used for data fitting in the Origin software,
suggesting two different modes of interaction. Overall, the
interactions between these peptides and the serum albumins are
weak, with the strongest dissociation constants (KD) in the low
millimolar range.
Antimicrobial and hemolytic activities
All the peptides were assayed for bactericidal activity against B.
subtilis, S. aureus and E. coli, in sodium phosphate buffer
supplemented with tryptic soy broth (Table 3). The concentrations
killing 99.9% of the inocula (LD99.9) are in general agreement with
antimicrobial minimum inhibitory concentration (MIC) data for
similar peptides that have been used in previous studies
[18,40,41,44], although there are small discrepancies which can
be attributed to differences in assay conditions and bacterial strains.
In general, all the modifications have significant effects on
peptide microbicidal activity. The strains of the Gram positive
species, S. aureus and especially B. subtilis, are more susceptible to
killing than the Gram negative E. coli strain. The Combi-based
peptides are generally more potent as antimicrobials compared to
the corresponding LfcinB-based hexamers. This is perhaps not
surprising given that the primary sequence of the former peptide
was obtained after extensive screening of a combinatorial library.
Com3 and especially Lfc3 are the least cationic peptides and as
a result they display the lowest activity in their respective series. In
fact, their activities against E. coli are negligible. On the other
Table 2. Fragments identified by MALDI-MS from 75 min
peptide incubations in diluted human serum at 37uC
a.
Original Peptide Fragment mass (Da) Assignment
Lfc3 687.3 CH3CO-RRWQ
559.3 CH3CO-RRW
Lfc4 687.4 CH3CO-RRWQ
559.3 CH3CO-RRW
Lfc5 985.1 Single Cut
b
Lfc7 960.3 RWQWRM
806.2 WQWRM
Lfc8 1544.8 Single Cut
b
943.5 KKLGRRW/KLGRRWQ
c
815.5 KLGRRW/LGRRWQ
c
Com2 745.3 CH3CO-RRWW
Com4 745.4 CH3CO-RRWW
559.3 CH3CO-RRW
aOnly peptides with observed intermediate fragments are listed here.
bThese fragments correspond to backbone cyclized peptides with one
hydrolyzed peptide bond.
cUnambiguous assignment of these fragments was not possible.
doi:10.1371/journal.pone.0012684.t002
Table 3. Antimicrobial activities of the short LfcinB and
Combi peptides.
Peptide 99.9% Lethal Dose Concentration (LD99.9) (mM)
B. subtilis S. aureus E. coli
Lfc1 7.5 30 60
Lfc2 1.9 15 15
Lfc3 60 .120 120
Lfc4 3.8 60 15
Lfc5 1.9 7.5 7.5
Lfc6 0.9 3.8 15
Lfc7 0.9 7.5 15
Lfc8 #0.45 15 3.8
Lfc9 #0.45 #0.45 1.9
Com1 1.9 7.5 60
Com2 0.9 30 30
Com3 7.5 30 120
Com4 0.9 7.5 7.5
Com5 #0.45 7.5 30
Com6 0.9 0.9 3.8
Com7 #0.45 1.9 30
doi:10.1371/journal.pone.0012684.t003
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amidation as with Lfc2 and Com2, there is an increase in potency
compared to Lfc1 and Com1. However, this advantage is not all-
encompassing as seen by the reduced activity of Com2 against S.
aureus compared to Com1. The activities of the peptides with both
end caps do not simply reflect an additive combination of these
opposing influences. Against B. subtilis and E. coli, Lfc4 shows
similar activities compared to Lfc2. However, against S. aureus, the
effect of N-terminal acetylation is stronger and the peptide is less
active than Lfc1. On the other hand, the acetylated N-terminus in
Com4 is beneficial and has a synergistic effect with the C-terminal
amidation so that its activity against S. aureus and E. coli is
improved compared to Com2.
The cyclized peptides are considerably more active than their
linear counterparts. While cyclization by backbone peptide linkage
improves the potency of the short antimicrobial peptides, disulfide
bridging between two added terminal disulfides appears to be even
better. This may in part be due to the amidated C-termini of the
disulfide bridged peptides that was chosen to be included in our
design of optimal antimicrobial peptides to maximize the net
charge. Com7 was also designed as a complement to Com6 due to
the greater activity of its linear counterpart. The modification of
both termini in Com7 gives mixed results compared to Com6 with
an improvement in activity against B. subtilis, the same level of
activity against S. aureus, and being less effective against E. coli.
The 11-mer LfcinB-derived peptides show greater activities
than the hexamer peptides. This reflects the higher number of
positively charged and hydrophobic side chains in the sequence of
the longer peptides. Lfc9 and Lfc8 are once again very active
compared to their linear version, Lfc7, with the exception of Lfc8
losing some activity against S. aureus.
The peptides were also tested for cytotoxicity with hemolytic
assays. None of the peptides are hemolytic and therefore, they
should be associated with high therapeutic values.
Antimicrobial activities in the presence of serum
In order to be able to make a direct comparison with our serum
stability measurements, a few peptides were selected to be tested
for antimicrobial activity in 25% human serum (Table 4). The B.
subtilis and S. aureus strains were initially chosen for these assays
because of the high activities associated, however the B. subtilis
strain did not grow in serum conditions. All LD99.9 values are
higher compared to the initial assays in 10 mM sodium phosphate
buffer. Contributing factors to this general loss in activity could be
the increased ionic concentration, interactions with serum
components such as albumin or other proteins, and peptide
degradation. Both hexamers with unprotected termini, Lfc1 and
Com1, are no longer active while the cyclized short peptides
remained fairly antimicrobial. In human serum, Lfc5 and Lfc6 are
equally anti-staphylococcal. This reflects a greater loss of activity
for Lfc6, but also coincides with the lower serum stability that this
peptide has compared to Lfc5 (Fig. 2C). The activities of the
cyclized Com peptides were all lowered equally with a 16-fold
increase in LD99.9 values compared to activities in serum-excluded
media and this agrees with their similar stability profiles (Fig. 2D).
Discussion
Current antimicrobial peptide research generally focuses on the
discovery and development of new peptides with superior activity.
However, little attention has been paid so far to characterizing
their behavior in their intended clinical environment. Important
pharmacokinetic aspects to consider about the peptide drug
candidates include their in vivo activity, cytotoxicity, circulation
and targeting, degradation as well as clearance, and side effects. It
has been reported that the in vivo stability of peptides in blood is
well modeled by in vitro stability in serum or plasma [49].
The hexameric peptides studied here are rich in Trp- and Arg-
residues, which are known to have high antimicrobial activity and
low hemolytic activity [3,18,44]. Confocal microscopy studies and
fluorescent dye leakage assays show that, like buforin and several
other peptides [50], these short linear peptides localize to the
cytoplasm of bacterial cells and are not highly disruptive to model
membranes resembling bacterial membranes. Therefore, an
intracellular mechanism of action is at least partially responsible
for their antimicrobial activity, presumably by binding to and
interfering with RNA and DNA synthesis [9,14,45]. However,
peptide/membrane interactions remain important as they can
modulate selectivity even when a peptide is not membrane
permeabilizing [51]. The originally studied Lfc2 and Com4
peptides were found to be unstructured in aqueous solution and
they become ordered and adopt a well-defined conformation when
bound to lipid membranes [42,43]. The micelle-bound structures
of these peptides as determined by NMR spectroscopy are
amphipathic with a positively charged side consisting of three
comparatively flexible Arg side chains and a hydrophobic side
consisting of the aromatic residues that are embedded in the
interfacial region of the membrane [52].
The antimicrobial data reinforces the notion that C-terminal
amidation improves peptide activity, most intuitively by removing
a negative charge. In terms of proteolytic susceptibility, the
protection of the C-terminus alone has a negligible effect.
Supporting mass spectrometry data detect only peptide fragments
that had two or three residues missing from the C-terminal ends of
the peptides after 75 min serum incubation. The absence of a
fragment that is missing only one residue suggests that serum
endopeptidases have to cleave near the middle of the peptides
before a carboxypeptidase will utilize the peptide as a substrate.
N-terminal acetylation decreases antimicrobial activity although
there may be some cases where the combination of both
modifications is even better for peptide activity as seen with
Com4. This potentially beneficial modification is not employed as
often as C-terminal amidation alone. The serum stability assays
and subsequent mass spectrometry data indicate that the terminal
end caps are somewhat advantageous for proteolytic stability as
well. N-terminal acetylation confers notable resistance against
serum aminopeptidases. There is even greater improvement in
combination with carboxyamidation. This suggests that these
modifications serve not only to protect against exopeptidases, but
also endow the peptides with greater structural stability so that
they are more resistant to endoproteases. However, the linear
Table 4. Anti-S. aureus activities of selected peptides in 25%
human serum.
Peptide LD99.9
Lfc1 .120
Lfc5 60
Lfc6 60
Com1 .120
Com5 30
Com6 15
Com7 30
doi:10.1371/journal.pone.0012684.t004
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counterparts.
Peptide cyclization greatly improves both the serum stability
and microbicidal activity of the peptides. NMR studies of Com5
have shown that the peptide forms a reasonably defined structure
in aqueous solution, but the micelle-bound peptides have
increasingly similar structures, particularly converging around
the aromatic residues [18]. The Trp and Phe side chains point
toward one side of the backbone ring and form a better defined
hydrophobic face that is stabilized by interactions with the micelle.
Between the two cyclization strategies, disulfide bonding by
terminal cystines is clearly more advantageous for antimicrobial
activity than backbone linkage. In the case of Lfc5 however, its
higher serum stability compensated for the lower activity so that its
activity in serum is close to that of Lfc6. Due to the close stability
profiles of the cyclic Com peptides, the disulfide-bonded peptides
remain the most potent peptides in human serum, particularly
Com6.
The longer LfcinB-derived peptides have the same benefits from
cyclization for antimicrobial activity. This trend agrees with other
peptides of similar sizes such as indolicidin and pyrrhocoricin
[15,19]. The previously determined micelle-bound NMR struc-
tures of Lfc7 and Lfc9 show that the cyclized peptide is more
amphipathic, with its hydrophobic side chains embedded deeper
into the membrane to give rise to better activity than the linear
peptide [14]. With the full length LfcinB however, the native
disulfide bond that connects the ends of the peptide does not have
a significant functional role, as seen by the similar activities
between the oxidized and reduced forms of the peptide. While the
disulfide is essential for stabilizing the b-sheet structure of LfcinB
in aqueous solution, the presence of the shorter ‘‘active center’’
appears to govern the antimicrobial activity.
The improved structural rigidity of the backbone-cyclized 11-
mer does not translate into the remarkable protease stability that is
observed with the related backbone-cyclized hexameric peptide.
Thus, there is a greater advantage in constraining shorter peptides
so that their backbones are less inviting substrates for serum
proteases. Evidently, the shorter length of Lfc5 presents less
possible active sites for endoproteases than Lfc8. This is supported
by the observation that the major fragments from the Lfc8
incubation with human serum result from cleavage sites outside of
the RRWQWR sequence. Interestingly, the Lfc8 fragments are
completely different from the Lfc7 intermediates. This indicates
that the linear and cyclic peptides differ in conformation so that
the sites most vulnerable to proteolysis are not common to both
peptides. In the case of the 20-residue pyrrhocoricin, a cyclic
derivative incorporating a 9-residue linker was observed to be even
less stable in human serum than the native peptide [19].
Another major serum component that may affect the action of
these antimicrobial peptides is serum albumin. In this work, ITC
experiments were carried out to study the thermodynamics of BSA
and HSA binding to the Trp- and Arg-rich peptides. All of the
ITC results obtained were comparable to each other, with
millimolar affinities calculated from the curve fittings. These weak
interactions likely have little effect on peptide stabilities or activities
in the serum, although they cannot be ruled out as a contributing
factor because of the high concentrations of HSA in human serum.
Comparatively, Com4 has been shown by ITC to interact with
negatively charged membranes with micromolar affinity [45].
Hence, there should be little competition from serum albumin to
sequester the peptides away from the bacterial cells. Another
possible consequence of the weak interactions could be increased
trafficking of the peptide through the circulatory system, given the
transporting role of albumin for many molecules such as hormones
and fatty acids. In another study, trimeric peptides that interact
with albumin at a 1:1 ratio and a micromolar KD were found to be
compromised in their antimicrobial activity due to the addition of
BSA to the in vitro assays [33].
There are many degradative enzymes present in the human
circulatory system. Serum proteases have regulatory roles for
enzymes and other proteins involved in the immune system and
blood clotting. As well, proteolytic activity serves to limit the
lifetimes of blood proteins and peptides such as antibodies and
hormones. The issue of peptide degradation will grow in
importance as more peptide candidates with promising levels of
antimicrobial activity enter the clinical stages of drug develop-
ment. For example, recent studies have used fusogenic liposomes
containing the RRWQWR peptide (Lfc1) to kill cancer cells [53].
The modified peptides discussed here could have improved
anticancer activity and perhaps be delivered more directly.
In this study, the effects of several simple modifications were
explored for short Trp- and Arg-rich peptides on their proteolytic
stability. The serum degradation profiles of the peptides also give a
first indication as to their resistance against secreted bacterial
proteases. However, the proteolytic stabilities determined here do
not have a clear correlation with biological activities, which
emphasizes that the modifications also affect the peptides’
antimicrobial mechanisms. The principles revealed here regarding
end capping, peptide cyclization and peptide length will help guide
the design of optimal antimicrobial, and possibly anticancer,
candidates for further pharmaceutical development.
Materials and Methods
All peptides were synthesized using standard 9-fluorenyl-
methyoxycarbonyl (Fmoc) chemistry and purified by HPLC to
.95% purity. They were obtained from Anaspec, Inc (San Jose,
CA) except for Com7, which was purchased from 21
st Century
Biochemicals (Marlboro, MA). Male human serum (H-4522),
.96% pure BSA (Lot 128H0656), and .99% pure HSA (Lot
97H7604) were obtained from Sigma-Aldrich. The concentrations
of the peptides and the albumins were calculated by UV
absorption at 280 nm using extinction coefficients determined by
ProtParam [54].
Serum stability assay
Peptide stabilities were assayed in diluted serum as previously
described [55]. 25% human male serum was centrifuged at 13,000
rpm for 10 min to remove lipids and the supernatant was collected
and incubated at 37uC for at least 15 min. The assay was initiated
upon the addition of the test peptide to the serum for a final
peptide concentration of 5 mM. 200 mL aliquots of the incubations
were taken for the following time points: 0, 30, 75, 120, 240, 390
and 540 min. The aliquots were mixed with 40 mL of 15%
trichloroacetic acid (TCA) and incubated at 4uC for at least
15 min to precipitate serum proteins. In the case of Com5 and
Com6, 5 mL of 1 M NaOH was supplemented to the TCA to
prevent peptide precipitation. The supernatant was collected for
each sample after centrifugation at 13,000 rpm for 10 min and
stored at 220uC. These assays were performed in triplicate.
Reverse phase high performance liquid chromatography (RP-
HPLC) analysis was performed with an AKTA Purifier from
Amersham Biosciences (Westborough, MA) using an uRPC C2/
C18 ST 4.6/100 column from Pharmacia Biotech (SanJose, CA)
of the following dimensions: bed length 100 mm, i.d. 4.6 mm,
120A ˚. Individually thawed samples were injected through a
100 mL loop, after which a linear gradient was run from 100%
solution A (0.05% trifluoroacetic acid (TFA) in filtered water) to
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rate at 0.5 mL/min. The relative concentrations of the remaining
soluble peptides were analyzed by the integration of the
absorbance at 215 nm as a function of retention time using the
Analysis module of the Unicorn software package.
MALDI-TOF mass spectrometry
Samples from the serum stability assay of each peptide after
75 min incubation time were analyzed for peptide fragments by
MALDI-TOF mass spectrometry with a Voyager DE-STR (Applied
Biosystems) using the two layer method. Briefly, a sinapinic acid
(Sigma S8313) matrix solution of 20 mg/mL in acetone:methanol
(80:20) was placed on a MALDI target (0.5 mL) as a seed layer and
allowed to dry. A second matrix solution of 10 mg/mL formic acid:
isopropanol: HPLC water (1:2:3) was mixed with equal amonts of
sample (diluted to ,1–5 mM in formic acid: isopropanol: HPLC
water solution) and 0.5 mL of mixture was placed on top of seed layer
and allowed to dry. The MALDI-TOF was operated in the linear
mode and calibrated externally using a protein mixture of insulin,
myoglobin and cytochrome c.
Isothermal titration calorimetry
ITC experiments were performed at 25uC on a Microcal VP-
ITC microcalorimeter with data analysis performed with the
Microcal Origin software. The sample cell contained 0.1 mM of
either BSA or HSA dissolved in 20 mM HEPES, 100 mM NaCl,
pH 7.9. The syringe was loaded with 2 mM test peptide in the
same buffer, and each titration point resulted from 5 mL injections
following an initial 2 mL injection. Separate control experiments
were also performed to account for heats of dilution/mixing.
Bactericidal assays
The peptides were tested for microbicidal activities against
Bacillus subtilis ATCC6633, Escherichia coli ML35, and Staphylococcus
aureus 42D as previously described [56]. Suspensions of logarith-
mically growing test bacteria were incubated on a microtiter plate
at a concentration of 10
5 colony-forming units/mL with various
peptide dilutions. The medium was 100 mL of 10 mM phosphate
buffer pH 7.0 supplemented with 1% (v/v) of tryptic soy broth
(TSB). For later assays, human male serum was also added to a
final concentration of 25%. 10 mL aliquots were collected at time
0 h and after 2 h of incubation on a rotary shaker (300 rpm) at
37uC. These were plated on blood agar plates and incubated
overnight at 37uC. The Lethal Dose concentration (LD99.9) was
determined, corresponding to the concentration killing .99.9% of
the inoculum at 2 h. These experiments were performed in
duplicate.
For the testing of the peptides’ activities in different conditions,
e.g. with serum, we use the same cut-off for activity as defined for
Minimum Bactericidal Concentration (MBC), i.e. a 1000-fold
reduction of the inoculum. However, we designate this peptide
concentration with the more general term LD99.9 which can be
applied to the specified conditions of the experiments performed
here.
Hemolysis assays
The peptides were also tested for hemolytic activity in assays
using red blood cells from heparinized human blood as previously
described [57]. Fresh human blood was centrifuged at 1500 rpm
for 10 min as 4uC and washed with phosphate buffered saline,
pH 7.3. Red blood cells were diluted to 1% and incubated with
various peptide dilutions for 1 h at 37uC. These incubations were
then centrifuged at 4000 rpm for 5 min and the supernatant was
collected for absorbance measurements at a wavelength of
540 nm. Controls for 0% and 100% hemolysis were determined,
with the latter condition defined by lysis by 1% Triton X-100.
Effective Concentrations for 50% hemolysis, EC50, were deter-
mined from the resulting dose-response profiles.
Supporting Information
Figure S1 Example ITC isotherms of 2 mM peptide into
0.1 mM serum albumin at 25uC, fitted using two-site modeling.
Profiles of A) Lfc8 titrated into HSA (strongest KD =0.15 mM),
and B) Com7 titrated into BSA (strongest KD =0.21 mM).
Found at: doi:10.1371/journal.pone.0012684.s001 (0.46 MB TIF)
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